Grand Rounds by OncoDaily: AI in Oncology Edition

Grand Rounds by OncoDaily: AI in Oncology Edition

OncoDaily Announces “AI Grand Rounds Q&A and Networking Session” at ASCO 2026

OncoDaily will host the AI Grand Rounds Q&A and Networking Session during ASCO 2026, with ZS serving as the exclusive partner. The session will explore the expanding role of artificial intelligence in oncology and its implications for cancer care, research, and clinical practice. The event will take place in Chicago during ASCO 2026.

Event Details

Date: May 30
Time: 5:00–8:00 PM
Location: Hyatt Regency McCormick Place Chicago 2233 S Martin Luther King Dr, Chicago, IL 60616, United States

Registration will be approved after completing the form.
Registration is available online

Co-Chair

ImagesName
Douglas-Flora - OncoDaily

Douglas Flora MD, LSSBB, is board-certified medical oncologist, cancer survivor, and executive leader, he serves as Executive Medical Director of the Yung Family Cancer Center at St. Elizabeth Healthcare and Editor-in-Chief of AI in Precision Oncology. Author of Rebooting Cancer Care and President-Elect of the Association of Cancer Care Centers (ACCC), he is dedicated to advancing prevention, early detection, innovation, and equity across the cancer care continuum. As CEO of TensorBlack and a frequent keynote speaker, he champions the responsible integration of AI and emerging technologies to transform oncology while keeping compassionate, patient-centered care at the forefront.

Speakers

ImagesName
OncoDailyCristian Massacesi, MD, is Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, overseeing global early- and late-stage development across oncology/hematology, neuroscience, immunology, and cardiovascular diseases, with more than 100 clinical trials and a team of ~6,000.
A trained medical oncologist, he has over 20 years of drug development experience. Prior to joining BMS in August 2025, he served as Chief Medical Officer of AstraZeneca and Alexion, and Oncology Chief Development Officer at AstraZeneca, leading over 150 clinical studies and multiple regulatory approvals. He also held senior R&D roles at Pfizer and Novartis.
He earned his MD from Marche Polytechnic University, trained at the Royal Marsden Hospital and other leading institutions, and has authored over 50 peer-reviewed publications.
ASCO AI- OncoDailyDr. Debra Patt is a practicing oncologist and breast cancer specialist in Austin, Texas, and Executive Vice President of Texas Oncology, focusing on healthcare policy and strategic initiatives. She also serves as managing partner for the Central Texas, Gulf, and Rio Grande Valley regions since 2023.
She is the Medical Director for Public Policy for The US Oncology Network and has testified before the US Congress and Senate to protect cancer care access. Dr. Patt is President of the Community Oncology Alliance, a member of the ASCO Board of Directors, and chairs ASCO’s Artificial Intelligence Task Force.
She is also a professor at Dell Medical School at The University of Texas at Austin and is active in advancing digital healthcare tools in oncology.
OncoDaily

Pavankumar Anné is a Principal in the Boston office of ZS and leads the firm’s Global Oncology and Precision Medicine Practice. With over 15 years at ZS, he has supported oncology companies across medical, marketing, and sales functions, with experience spanning most tumor types and deep expertise in commercialization strategy and organizational design.
He has led market landscape assessments, disease area and brand strategies, and partnered with oncology diagnostics companies on portfolio strategy, sales planning, customer segmentation, and competitive analysis.
Pavan holds an MBA from Yale School of Management and a BS in Mechanical Engineering from IIT Madras. Prior to ZS, he worked as a Design Engineer at Caterpillar Inc.
OncoDaily

Dr. Sanjay Juneja is a triple board-certified hematologist and medical oncologist and Vice President of AI & Medical Informatics at Tempus AI, where he leads clinical AI strategy in oncology. He is the author of “We Need to Talk About Cancer” and creator of “TheOncDoc,” reaching over 750,000 professionals worldwide.

He maintains a clinical practice with Citrus Oncology, completed Harvard’s AI in Healthcare program, and serves on the Editorial Board of AI in Precision Oncology. His honors include Targeted Oncology’s 2024 Oncology Icon, a White House invitation, 40 Under 40, and recognition among the Capital Region’s Top 500 Most Influential Leaders for three consecutive years.

Featured in major outlets like The Washington Post and Bloomberg, he is also co-founder of TensorBlack Inc. His AI and healthcare podcast has over 5 million downloads in 110+ countries.
SV HeadshotSunil Verma, MD, is Senior Vice President and Global Head of the Oncology Franchise at AstraZeneca, where he leads global oncology strategy and a late-stage portfolio across multiple tumor types. With more than 25 years of experience spanning clinical practice, academia, and pharmaceutical leadership, he has played a key role in advancing cancer research and innovation.
Dr. Verma has contributed to more than 50 major clinical trials and authored over 125 peer-reviewed publications that have helped shape oncology practice. Before joining AstraZeneca, he served as Professor and Academic/Clinical Department Head of Oncology at the University of Calgary, as well as Medical Director of the Tom Baker Cancer Centre. He is also widely recognized for his commitment to education, mentorship, and leadership development in oncology.

ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 13,000 employees in over 35 offices worldwide. To learn more, visit www.zs.com or follow us on LinkedIn.